A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

Non-squamous NSCLC Clinical Trial

Official title:
A Randomized, Double-blind, Phase 3 Bridging Study Evaluating the Safety and Efficacy of ABP 215 Compared With Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

Status Withdrawn

Clinical Trial Summary

The purpose of this research study is to assess the efficacy and safety of ABP 215 compared to Bevacizumab in Chinese patients with advanced non-small cell lung cancer (NSCLC).

Clinical Trial Description

Approximately 170 subjects will be randomized 1:1 in approximately 40 sites in China. This study consists of a screening period of up to 28 days, followed by a treatment period of 18 weeks, and an end of study visit 3 weeks after the last dose of investigational product or study-specified chemotherapy. After randomization, subjects will receive investigational product at a dose of 15 mg/kg administered every 3 weeks for 6 cycles followed by at least 4 and no more than 6 cycles of carboplatin and paclitaxel chemotherapy every 3 weeks. ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Metastatic Non-small Cell Lung Cancer (NSCLC)
Non-squamous NSCLC

Clinical Trial Details

NCT number	NCT04466917
Study type	Interventional
Source	Amgen
Contact
Status	Withdrawn
Phase	Phase 3
Start date	May 15, 2021
Completion date	November 13, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04413201` - AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC	Phase 4
Active, not recruiting	`NCT04447118` - Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy	Phase 3
Completed	`NCT05261438` - Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Recruiting	`NCT03755869` - Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）	Phase 4
Not yet recruiting	`NCT05782426` - Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC	Phase 2
Recruiting	`NCT05751187` - Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients	Phase 2
Terminated	`NCT02454842` - Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients	Phase 2
Not yet recruiting	`NCT06206850` - Neo-Bio-ADAURA: A Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib	Phase 2